Novakand Pharma AB

Kancera (now Novakand Pharma) is a Swedish oncology biotech headquartered at Karolinska Science Park in Stockholm. It develops small molecule drugs controlling disease-promoting immune cells via the fractalkine axis. Lead candidate KAND567 is in two fully-funded Phase IIa trials for cardiac, renal and pulmonary injuries caused by hyperinflammation. Acquired CRO iNovacia. Listed on Nasdaq First North Premier.